Study M954
Study name | Liu DF 2022 |
Title | Effect of modified electroconvulsive therapy on neuro metabolites and magnetic resonance spectroscopy imaging signals in patients with refractory obsessive-compulsive disorder |
Overall design | The aim of this study was to investigate the effect of modified electroconvulsive therapy on neurometabolites and magnetic resonance spectroscopy imaging (MRSI) signals in patients with refractory obsessive-compulsive disorder (OCD). A total of 64 patients with refractory OCD were selected. The patients were randomly divided into a study group (modified electroconvulsive therapy group, n =32, with mean HAMD scores of 30.4) and a control group (control treatment group, n =32, with mean HAMD scores of 29.7). The treatment was performed 3 times a week with 12 times (4 weeks) as a course of treatment. Patients received 3 courses (12 weeks, 36 modified electroconvulsive therapy) of the treatment. The effects of modified electroconvulsive therapy on the neurometabolites were investigated by magnetic resonance spectroscopy imaging (MRSI) signals. Metabolite quantification was reported relative to total creatine as the reference peak. |
Study Type | Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive symptom; Depressive symptom with comorbidity; Depressive symptom with comorbidity; |
Criteria for depression | Not reported |
Sample size | 64 |
Tissue | Central; Brain; Prefrontal white matter and anterior cingulate cortex; |
Platform | MRS; MRS: Philips 3 Tesla Achieva/Intera Release 2.6.1 12.6 series whole body scanner MR device (Philips Medical Systems, Eindhoven, The Netherlands); |
PMID | |
DOI | |
Citation | Liu D, Liang R, Bai S, et al. Effect of modified electroconvulsive therapy on neuro metabolites and magnetic resonance spectroscopy imaging signals in patients with refractory obsessive-compulsive disorder. J Affect Disord. 2022 Jan 1;296:616-621. |
Metabolite | N-Acetyl aspartate/(Creatine and Phosphocreatine) ratio; Choline-containing compounds/(Creatine and Phosphocreatine) ratio; |
